Evaluation of lipid associated sialic acid as a tumor marker for gastrointestinal tract cancer

Abstract EN

The objective of this study was the evaluation of serum and tissue LSA level as tumor marker for gastrointestinal tract cancer (GIT).

LSA was measured in sera and tissues of 76 cancer patients (with different stages), 27 patients with benign GIT diseases and 30 healthy individuals.

Marker determination was done by spectrophotometric procedure of katopodis with resorcinol.

It was found significant (p < 0.001) elevations of serum LSA level in GIT cancer patients, when compared with those of benign and healthy individuals.

Serial estimation of serum LSA levels indicated a disease status dependent rises.

A trend of increasing serum LSA levels was obtained as the malignancy become more sever, i.

e., stage I to stage IV.

The sensitivity of LSA was 95 %.

Determination of tissue marker s contents revealed significant (p < 0.001) elevation of LSA in malignant tissue with respect to those of benign tumors.

Comparison of serum and tissue LSA contents indicated significant positive correlation for LSA in cancerous patients but not in those with benign diseases.

The results pointed out the benefits of LSA as tumor marker for GIT cancer.